Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$393.2MCash on Hand
29.4mo Cash Runway
Follow AVBP by emailGet an email when AVBP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about AVBP, unsubscribe in one click. Privacy
📣 What AVBP Says Is Next
first quarter of 2027 · Firmonertinib: “We plan to provide an update on firmonertinib in the first quarter of 2027 around the review of the FURVENT study. · Phase 1b Data for ARR-217.”
Company press release, Nov 9, 2026 · SEC filing
2H 2026 · “Top-line data from the global pivotal FURVENT Phase 3 (NCT05607550) study for first-line EGFR exon 20 insertion mutant NSCLC is anticipated in 2H 2026. · Initial Phase 1 data for ARR-217 .”
Company press release, Aug 12, 2026 · SEC filing
second half of 2026 · “Dosing of first patient with ARR-002 in a Phase 1 trial expected in the second half of 2026. 2026 Financial Results”
Company press release, May 11, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 9, 2026 ·
Earnings Reported Q3 2026 results with $393.2M cash expected to fund operations to mid-2028. R&D expenses were $118.9M and G&A $28.3M for nine months. Net loss was $133.5M. Dr. Stuart Lutzker retires as R&D President and director effective December 1, 2026, and Dr. Priti Patel will lead R&D. Form 8-K · SEC filing · Press release
Nov 9, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Oct 26, 2026 ·
Clinical trial ArriVent reported initial Phase 1 data for CDH17-targeted ADC ARR-217 (MRG007) at ESMO 2026, with a 44.8% (13/29) objective response rate at the 6 mg/kg Q3W dose in pretreated colorectal cancer patients and a 93.1% (27/29) disease control rate. Form 8-K · SEC filing · Press release
Oct 19, 2026 ·
Clinical trial Announced publication in Cancer Cell of FURTHER Phase 1b results for firmonertinib in EGFR PACC-mutant NSCLC, reporting 43% (160 mg) and 68% (240 mg) confirmed ORR and 11.1- and 16.0-month median PFS by blinded independent central review in front-line patients. Intracranial confirmed ORR was 47% (8/17). Form 8-K · SEC filing · Press release
Oct 13, 2026 ·
Clinical trial ArriVent dosed its first U.S. patient in a Phase 1 trial of ARR-002, a MUC16/NaPi2b dual-target ADC for ovarian and endometrial cancer. The company also licensed ARR-002 rights in Greater China to Shanghai Allist Pharmaceuticals in August 2026. Form 8-K · SEC filing · Press release
Oct 6, 2026 ·
Clinical trial Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed its primary PFS endpoint by BICR: median PFS 11.0 months at 240mg and 8.4 months at 160mg vs 9.5 months control (p=0.0654 for 240mg). Safety was consistent with prior studies. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Deal Licensed ARR-002 rights in Greater China to Allist for up to $80.6 million in upfront, milestone and royalty payments, and reported Q2 2026 cash and investments of $373.1 million, expected to fund operations into 2028. Form 8-K · SEC filing · Press release
Aug 12, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2027 · Phase 1 · Recruiting · Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer. Registry primary completion date, not a results date
Mar 2028 · Phase 1 · Recruiting · A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors Registry primary completion date, not a results date
Oct 2028 · Phase 3 · Recruiting · A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR)… Registry primary completion date, not a results date
Feb 2029 · Phase 3 · Recruiting · Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With… Registry primary completion date, not a results date
Oct 2026 · Phase 3 · Active Trial · Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20… Registry date passed, readout not confirmed
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
AVBP holds $393.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $40.1M/quarter from operations,
an estimated runway of 29.4 months at that rate (BioRadar estimate, not company guidance).
Share count 51,723,074 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full AVBP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AVBP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.